Amgen/Horizon Therapeutics: FTC Staff Probes Buyer’s Past Drug-Price Increases and Alleged Anticompetitive Tactics 

Published on Mar 22, 2023

FTC staff reviewing Amgen’s (AMGN) proposed $27.8 billion acquisition of Horizon Therapeutics (HZNP) is probing the acquirer’s track record of raising drug prices and allegedly shielding its products from competition, sources familiar with the matter said.   The staff is considering whether Amgen’s purchase of Horizon, a developer of treatments for rare autoimmune and severe inflammatory […]

Already have an account? Log in.

This article is currently locked and only available to subscribers. Request a trial to receive unlimited access to all articles.

View Only Unlocked Articles

Copyright ©2024 The Capitol Forum. All Rights Reserved.